More Antineoplastics (Unit 3 Howe Lecture 4)

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/22

encourage image

There's no tags or description

Looks like no tags are added yet.

23 Terms

1
New cards

microtubule agents
Vincristine (natura; products)

• Destabilizes microtubules & disrupts mitosis
• ALL, NHL, HD (as ‘Oncovin’ in BEACOPP & MOPP); others...
• Adverse events
– Bone marrow suppression, alopecia
– Neurotoxicity, constipation
• Neurotox. distinct from cisplatin (No
nephrotoxicity)
– SIADH: Syndrome of Inappropriate Antidiuretic
Hormone (aka vasopressin)
• Fluid retention  hyponatremia
– Headache, N/V, convulsions, coma
– Vesicant: use central line for admin
– Fatal if given intrathecally

2
New cards

vesicant drug extravasations

  • vincristine extravasation

  • Doxorubicin extravasation


3
New cards

microtubule agents Paclitaxel (taxol) (natural products)

• Stabilizes microtubules, blocks mitosis
• Breast and ovarian cancers
• Very promising results when given
i.p. rather than i.v. for ovarian cancer
• DLTs = peripheral neuropathy, myelosuppresion
• Also hypersensitivity
– Urticaria & bronchospasm
– From formulation (cremaphor)

4
New cards

topoisomerase inhibitors (natural products)

  • Type I Topoisomerases nick & reseal 1 strand of DNA

  • Type II Topoisomerases cut & rejoin 2 strands of DNA


5
New cards

irinotecan (topoisomerase inhibitors- natural products)

Rationale:

• Inhibits TopoI —> ssDNA breaks
• TopoI is over-expressed in some tumors


Tox/ADRs:

• Profuse diarrhea (“I ran to the can...”) = Myelosuppression

• Nausea/vomiting (oral); ~alopecia; metallic taste (when given i.v.)

6
New cards

etoposide (topoisomerase inhibitors- natural products)

Rationale/MOA:
- Inhibits Topo II —> irreparable dsDNA breaks

Tox/ADRs:

• DLT (dose-limiting toxicity) = myelosuppression
• Nausea/vomiting (oral); ~alopecia; metallic taste (when given i.v.)

7
New cards

doxorubicin (aka adriamycin or hydroxydaunorubicin) 3-fold mech

1. Binds/intercalates into DNA
2. Generates free radicals
 damage to DNA & lipids
3. Causes DNA strand breaks via inhibition of Topo II

8
New cards

tamoxifen

  • inhibits estrogen-dependent functions


9
New cards

anti-estrogens & anti-androgens (hormonal agents)

• In cancers arising from endocrine-regulated tissues, the
tumor cells often retain a trophic response to and/or
dependence on specific hormones


• Thus, blocking specific hormone function (e.g. via a
hormone receptor antagonist) can exert anti-tumor effect

10
New cards

how estrogen works on breast & breast cancer cells

  • estrogen enters the cell and binds to an estrogen receptor

  • the receptor binds to DNA which triggers cell proliferation


11
New cards

tamoxifen (an anti-estrogen)

*Same theory can be used for testosterone-dependent
tumors (e.g. anti-androgens for prostatic carcinoma)


uses:

  • ER+ breast cancers


tox/ADRs:

  • Very different MOA  Very different ADRs

  • Common: Hot flashes, menstrual changes, low LDL,
    vaginal discharge & uterine bleeding

  • Occasional: nausea (delayed), hypercalcemia, blood
    clots, cataracts, ‘chemo brain’


specials:

  • Competitive ER ‘antagonist’, but…

  • Acts as partial agonist in some tissues (endometrium,
    bone, liver); thus, technically a ‘SERM’ (selective
    estrogen response modifier), unlike other true
    antagonists (e.g. fulvestrant)

  • —> increased incidence of secondary endometrial cancer


12
New cards

STI571/Imatinib/Gleevec (kinase inhibitor)

  • world’s first treatment for a cancer based on its specific, genetic cause


however…


  • Despite its rational design, imatinib shows significant cross-
    reactivity/inhibition with other proteins (c-Kit, PDGFR – both tyrosine kinases)

  • Good News: Shows promise for use in tumors is which these proteins are
    causally dysregulated

  • Bad News: The human animal is more complex than even the most rational of designs (so far)

  • increasing emergence of primary & acquired resistance to imatinib


13
New cards

imatinib (a kinase inhibitor)

uses:

  • Ph+ CML & ALL; c-kit+ GIST (gastrointestinal stromal tumors)


ADME:

  • Complex interactions with CYP450s as both a
    substrate and an inhibitor ( high potential for drug-
    drug interactions)


tox/ADRs:

  • DLT = myelosuppression

  • edema (ankle, periorbital); N/V


specials:

  • First genotype-specific chemotherapeutic;

  • Cross-reactive with c-kit & PDGFR

  • Increasing emergence of 1o & 2o resistance

  • 2nd & 3rd gen BCR-Abl inhibitors developed based on
    molecular analysis of resistance-conferring mutations


14
New cards

CTLA4

—> ipilimumab

15
New cards

PD-1/PD-L1

—> pembrolizumab

16
New cards

(-) factors on T-cell when trying to kill tumor cell

  • PD-1

  • CTLA4


17
New cards

(+) factor on T-cell when trying to kill tumor cell

TCR

18
New cards

pembrolizumab (immune checkpoint inhibitors)

uses:

  • NSCLC (1st); melanoma,
    bladder, HD, RCC, HCC,
    HNSCC, cervical CA, …


rationale:

  • These cancers express
    PD-L1 that shields them
    from immune/T-cell
    recognition. Blocking PD-
    1 prevents this blockade.


tox/ADRs:

  • quite well-tolerated

  • Common: fatigue, myalgia,
    itch, some GI distress

  • Serious/rare: Pneumonitis;
    colitis; hepatitis


19
New cards

antimetabolites

  • methotrexate

  • 5-fluorouracil

  • 6-mercaptopurine


20
New cards

alkylating/DNA-damaging agents

  • cyclophosphamide

  • cisplatin

  • doxorubicin


21
New cards

topoisomerase inhibitors

  • doxorubicin

  • irinotecan

  • etoposide


22
New cards

microtubule poisons

  • vincristine

  • Taxol


23
New cards

targeted therapies

  • tamoxifen

  • imatinib/Gleevec

  • pembrolizumab